IOL Chemicals & Pharma: FY26 Investor Presentation - Revenue at ₹2,319.1 Cr, PAT at ₹137.7 Cr
IOLCP's Q4 FY26 standalone revenue rose 17.4% YoY to ₹619.5 crore, with PAT increasing 68.2% to ₹53.2 crore. FY26 revenue reached ₹2,319.1 crore, up 11.5% YoY, and PAT increased 36.4% to ₹137.7 crore. The company expanded Ethyl Acetate capacity to 1,20,000 MTPA and Acetic Anhydride to 32,000 MTPA. IOLCP aims for carbon neutrality by 2050, reducing Scope 1+2 emissions intensity by 8.8% in FY26.
The financial results indicate stable growth and capacity expansions suggest potential for future growth. Sustainability initiatives also contribute positively to the company's image.
The announcement highlights positive financial results, including increased revenue, EBITDA, and PAT, along with capacity expansions and sustainability initiatives.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) released its investor presentation on 21 May 2026, highlighting the financial results for the quarter and year ended 31 March 2026. The presentation, submitted in compliance with SEBI regulations, is also available on the company's website.
The standalone performance for Q4 FY26 shows revenue from operations at ₹619.5 crore, a 17.4% year-on-year increase. The Profit After Tax (PAT) stood at ₹53.2 crore, reflecting a 68.2% year-on-year growth, with a PAT margin of 8.6%. EBITDA was reported at ₹94.3 crore, a 39.8% increase year-on-year, with an EBITDA margin of 15.2%. For the full fiscal year FY26, the company reported revenue from operations of ₹2,319.1 crore, a 11.5% increase year-on-year. EBITDA for FY26 was ₹290.4 crore, a 29.3% increase, with a margin of 12.4%. The PAT for FY26 was ₹137.7 crore, up by 36.4% year-on-year, with a PAT margin of 5.9%.
The company has expanded its Ethyl Acetate capacity to 1,20,000 MTPA and Acetic Anhydride capacity to 32,000 MTPA. They have also installed a Triacetin capacity of 6,000 MTPA and enhanced Pantoprazole capacity to 276 MTPA. IOLCP has a team of over 3,000 employees and is among the top global producers of Iso Butyl Benzene (IBB). The company has also purchased 101 acres on Chandigarh-Bathinda Highway for new site development. They have a debt-to-equity ratio of 0.08. The company is committed to becoming carbon neutral by 2050 and has reduced Scope 1+2 emissions intensity by 8.8% in FY26.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.